01
Angel Investor Round
October 2025
The first step for Solstis is securing an angel investment round. This early capital will provide the foundation for prototype validation, and intellectual property filing. The focus will be on leveraging personal and professional networks to attract mission-aligned investors who are passionate about healthcare innovation. With a target raise of $100K, this round will also enable us to bring on key advisors in medtech engineering, FDA compliance, and healthcare partnerships. By the end of this stage, we aim to demonstrate strong early traction and position Solstis for larger-scale funding.
November 2025
Solstis will move quickly to secure intellectual property protection to safeguard its unique value proposition. This involves working closely with a patent attorney to file a provisional patent covering the AI-driven guidance system, the physical design of the kit, and the integrated workflow that differentiates our product. Within 12 to 18 months, the provisional filing will be converted into a non-provisional patent and extended through international filings via the Patent Cooperation Treaty (PCT) to protect our innovation in major global markets. In addition, we will register trademarks for our brand name, Solstis, as well as our tagline, “Confident Care, Anywhere,” to build brand identity and recognition. By protecting both our technology and branding early, we ensure that Solstis is well-positioned for long-term defensibility and investor confidence.
02
Intellectual
Property
Filling
03
Venture Capital Investment
December 2025
After initial validation and IP filing, Solstis will pursue a venture capital investment round to accelerate growth and bring the product to market. By this stage, we expect to have a working prototype, an established advisory board, and strong validation of the market need, which will allow us to present a compelling case to early-stage healthtech and medtech investors. The goal is to raise around $1 million in Series A funding, which will support scaling operations and advancing regulatory efforts. The funds will also go toward manufacturing partnerships and preparing for commercialization. This round will serve as the inflection point that transforms Solstis from a promising concept into a fully investable, growth-stage company.
January 2026
Achieving FDA compliance is a critical step in bringing Solstis to market as a Class II medical device. This process begins with engaging regulatory consultants to map out the De Novo clearance pathway and implementing a Quality Management System (QMS) that meets FDA standards. Over the course of 12 to 24 months, we will conduct verification and validation studies, bench testing, and usability testing to demonstrate product safety and reliability. Clinical testing may also be required, depending on the scope of the guidance system, determined by the FDA. Once the data is collected, we will prepare and submit the necessary documentation for FDA review, aiming to secure clearance within 24 to 36 months of development. This stage not only ensures compliance with regulatory standards but also enhances credibility with investors, partners, and customers, establishing Solstis as a trusted solution in the healthcare market.
04
FDA Compliance for a Class II Medical Device
05
Crowdfunding
February 2026
With FDA clearance achieved, Solstis will launch a crowdfunding campaign to validate demand, raise awareness, and secure pre-orders. Platforms such as Kickstarter or Indiegogo will be used to reach both early adopters and broader consumer audiences, particularly targeting campers, travelers, and young families. The campaign will feature compelling storytelling through high-quality demo videos, testimonials, and clear messaging about safety and reliability. More than just a source of revenue, crowdfunding will serve as a powerful marketing tool to build a loyal community around Solstis, creating excitement ahead of our full launch. Our target is to raise at least $500,000 in pre-orders, attract hundreds of early backers, and generate media coverage in the healthtech press. This stage will solidify market demand and give us momentum heading into commercialization.
March 2026
The final step of the roadmap is the official launch of Solstis. With regulatory clearance and pre-order momentum, we will open direct-to-consumer sales through an e-commerce platform while also pursuing partnerships with various retailers. Simultaneously, we will expand into the B2B market, forming partnerships with companies, schools, and corporate wellness programs that can integrate Solstis into their safety offerings.